News & Updates

Phase II data presented at CROI 2024 demonstrated the ability of an investigational, long-acting, oral once-weekly regimen comprising islatravir, a nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class capsid inhibitor, to maintain viral suppression at week 24 in virologically suppressed people living with HIV (PWH).

Patients with complicated urinary tract infection (UTI) may fare better with cefepime–taniborbactam than with meropenem, with the combination having been associated with much higher treatment success rates in the phase III CERTAIN-1 trial.

Breakthrough COVID-19 is not uncommon following pre-exposure prophylaxis (PrEP) with tixagevimab/cilgavimab among patients with systemic autoimmune rheumatic diseases (SARDs), reports a recent study. However, most of the infections in this high-risk population are not severe.

Being infected with COVID-19 may reduce the sexual function of cisgender women, while having long COVID can worsen the already impaired sexual function as compared to those who do not have long COVID, a study has found. However, the mechanisms as to why these effects occur remain unclear.

Bacterial respiratory tract infection normally occurs in infants requiring early intubation in the emergency department (ED) for viral bronchiolitis, according to a study. However, respiratory bacterial codetection appears to shorten the duration of mechanical ventilation (MV) and length of stay (LOS) of these patients in the intensive care unit (ICU).